Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia

Haematologica. 2005 May;90(5):695-6.

Abstract

We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker and for MRD monitoring.

Publication types

  • Evaluation Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Bone Marrow / chemistry*
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / pathology*
  • Leukemia, Myeloid / surgery
  • Male
  • Middle Aged
  • Neoplasm Proteins / genetics*
  • Neoplasm, Residual
  • Prognosis
  • RNA, Messenger / analysis*
  • RNA, Messenger / biosynthesis
  • RNA, Neoplasm / analysis*
  • RNA, Neoplasm / biosynthesis
  • Remission Induction
  • Survival Analysis
  • Tretinoin / therapeutic use
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Cytarabine
  • Tretinoin
  • Etoposide
  • fms-Like Tyrosine Kinase 3
  • Daunorubicin